Close Menu

Tecan

NuGen and WaferGen Biosystems are collaborating to develop and market workflows that combine NuGen's sample prep and preamplification technology with WaferGen's SmartChip high-density and –throughput real-time PCR system.

The deal will enable researchers to more easily perform high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace specimens, including formalin-fixed, paraffin-embedded tissue.

Geospiza and NuGen Technologies will combine their informatics and sample-prep products to provide a next- generation sequencing workflow targeted toward large disease research studies.

Under a co-marketing agreement, the companies will combine Geospiza's GeneSifter software with NuGen's Ovation and Encore sample prep reagents.

The deal is aimed at accelerating discoveries for large research studies.

While Biocius' RapidFire technology has traditionally been used by pharma firms for drug-screening work, "one of the key opportunities" Agilent sees is applying the platform "to the clinical proteomics space," a company official said.

New Products: Feb 15, 2011

Premium

Tecan and SciRobotics' Pickolo

At the Association for Mass Spectrometry's Applications to the Clinical Lab meeting this week, proteomics researchers highlighted the need for higher-throughput assays, with several introducing automated SISCAPA workflows employing instruments from vendors including Agilent Technologies and Thermo Fisher Scientific.

The new product, called the DeepSeq FFPE Solution, runs on the company's RDT 1000 microdroplet PCR instrument and allows researchers to discover rare mutations.

New Products: Feb 8, 2011

Premium

Complete Genomics' sequence data, New England Biolabs' NEBNext, Caliper Life Sciences' TruSeq protocols, CLC Bio and Omixon's Gapped SOLiD Alignment plug-in, DNAnexus' Variation Identification software, Johns Hopkins' Myrna and Crossbow releases

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.